Cancer Investigation最新文献_第9页

Assessment of Swallowing Function in Patients with Head and Neck Squamous Cell Carcinoma in High vs. Low Dose Cisplatin. 高剂量与低剂量顺铂对头颈部鳞状细胞癌患者吞咽功能的影响。

IF 2.4 4区医学

Cancer Investigation Pub Date : 2023-12-01 Epub Date: 2024-01-02 DOI: 10.1080/07357907.2023.2283452

Amber Veldman, Annika van Oosbree, Madisyn Braun, Aarabhi Gurumoorthy, William C Spanos, Steven Powell

引用次数: 0

Significance of the Pretreatment Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Predicting the Response to Neoadjuvant Chemotherapy and Survival Rates in Extremity Osteosarcoma: A Multicentre Prospective Study. 预处理中性粒细胞/淋巴细胞比率和血小板/淋巴细胞比率在预测四肢骨肉瘤对新辅助化疗的反应和生存率中的意义:一项多中心前瞻性研究。

IF 2.4 4区医学

Cancer Investigation Pub Date : 2023-12-01 Epub Date: 2024-01-02 DOI: 10.1080/07357907.2023.2283456

Amir Mohammad Arefpour, Maryam Garousi, Ahmad Foroughi, Saeed Hosseini, Mohadeseh Shahin, Seyed Alireza Javadinia

{"title":"Significance of the Pretreatment Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Predicting the Response to Neoadjuvant Chemotherapy and Survival Rates in Extremity Osteosarcoma: A Multicentre Prospective Study.","authors":"Amir Mohammad Arefpour, Maryam Garousi, Ahmad Foroughi, Saeed Hosseini, Mohadeseh Shahin, Seyed Alireza Javadinia","doi":"10.1080/07357907.2023.2283456","DOIUrl":"10.1080/07357907.2023.2283456","url":null,"abstract":"Objectives: We aimed to assess the effects of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios on the response to neoadjuvant chemotherapy and survival rates in patients with extremity osteosarcoma.Patients and methods: Patients with high-grade osteosarcoma admitted to oncologic centers affiliated with Iran University of Medical Sciences, Tehran, Iran from 2015 to 2021 were evaluated retrospectively to assess the impact of complete blood count-related parameters on the pathologic response after neoadjuvant chemotherapy. Then, patients were followed up prospectively to evaluate the survival rates. All patients received at least three cycles of cisplatin/doxorubicin regimen, preoperatively. In this study, the cut-off values for high neutrophil-to-lymphocyte and high platelet-to-lymphocyte ratio were considered 3.28 and 128, respectively.Results: One hundred eighty-six patients were enrolled. Patients with high neutrophil-to-lymphocyte ratio and high platelet-to-lymphocyte ratio had a significantly lower overall survival rates (20.7 [95% CI 18-23.5] month vs. 34.6 [95% CI 33.2-36], p = 0.003 and 21.9 [95% CI 20.2-23.6] month versus 35.3 [95% CI 33.9-36.7], p = 0.002; respectively). Moreover, disease-free survival of patients with high platelet-to-lymphocyte ratio was worse than patients with low platelet-to-lymphocyte ratio (20.4 [95% CI 18.4-22.4] month vs. 32.7 [95% CI 30.8-34.7], p = 0.02).Conclusion: Our study showed that neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios at the baseline can predict the survival of patients with high-grade osteosarcoma.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"816-820"},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107590307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer. 剂量密集多西他赛-环磷酸胺和表柔比星-铂（ddDCEP）：116例早期三阴性乳腺癌癌症患者的替代含铂方案分析。

IF 2.4 4区医学

Cancer Investigation Pub Date : 2023-10-01 Epub Date: 2023-11-17 DOI: 10.1080/07357907.2023.2278048

Ashish Singh, Josh Thomas Georgy, Anjana Joel, Divya Bala Thumaty, Ajoy Oommen John, Nithya Ramnath, Tarun K George, Parth Sharma, Shalom Patole, Grace Rebekah, Elanthenral Sigamani, Marie Therese Manipadam, Anish Jacob Cherian, Deepak Thomas Abraham, Mazhuvanchary Jacob Paul, Rajesh Balakrishnan, Patricia Sebastian, Selvamani Backianathan, Raju Titus Chacko

{"title":"Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer.","authors":"Ashish Singh, Josh Thomas Georgy, Anjana Joel, Divya Bala Thumaty, Ajoy Oommen John, Nithya Ramnath, Tarun K George, Parth Sharma, Shalom Patole, Grace Rebekah, Elanthenral Sigamani, Marie Therese Manipadam, Anish Jacob Cherian, Deepak Thomas Abraham, Mazhuvanchary Jacob Paul, Rajesh Balakrishnan, Patricia Sebastian, Selvamani Backianathan, Raju Titus Chacko","doi":"10.1080/07357907.2023.2278048","DOIUrl":"10.1080/07357907.2023.2278048","url":null,"abstract":"We assessed the efficacy, tolerability, and cost-effectiveness of a novel neoadjuvant regimen comprising docetaxel-cyclophosphamide alternating with epirubicin-cisplatin (ddDCEP) administered biweekly for 16 weeks in 116 patients with early triple-negative breast cancer. This regimen achieved a high pathological complete response (ypT0/TisN0) rate of 55.2% and favorable survival outcomes (30-month event-free survival, 91.2%; overall survival, 97%). Febrile neutropenia was observed in 4.3% of patients, and 98% completed at least six of eight cycles. ddDCEP was more cost-effective than contemporary carboplatin-based regimens. This novel approach offers an economically viable and effective alternative to current chemoimmunotherapy regimens, and merits further investigation.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"789-802"},"PeriodicalIF":2.4,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71420900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond the Horizon: A Cutting-Edge Review of the Latest Checkpoint Inhibitors in Cancer Treatment. 超越地平线：2022年癌症治疗中最新检查点抑制剂的前沿综述。

IF 2.4 4区医学

Cancer Investigation Pub Date : 2023-10-01 Epub Date: 2023-11-17 DOI: 10.1080/07357907.2023.2267675

Marc Boutros, Fouad Attieh, Antoine Chartouni, Johnny Jalbout, Hampig Raphaël Kourie

{"title":"Beyond the Horizon: A Cutting-Edge Review of the Latest Checkpoint Inhibitors in Cancer Treatment.","authors":"Marc Boutros, Fouad Attieh, Antoine Chartouni, Johnny Jalbout, Hampig Raphaël Kourie","doi":"10.1080/07357907.2023.2267675","DOIUrl":"10.1080/07357907.2023.2267675","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have emerged as a revolutionary paradigm in oncology, offering a potent arsenal against various malignancies by harnessing the body's own immunological prowess. In a whirlwind of advancement, an abundance of new ICIs have come to light, rendering it a Herculean task for physicians to remain au courant with the rapidly evolving landscape. This comprehensive review meticulously explores the crescendo of clinical investigations and FDA approvals that have come to light during 2022 and 2023, showcasing the metamorphic impact of ICIs in cancer therapeutics. Delving into the pith of pivotal Phase 3 trials across diverse cancer types - including lung, renal, melanoma, and more - the review illuminates the significant strides made in enhancing patient outcomes, alongside the unveiling of novel ICIs that have garnered attention in the oncological community. The analysis extends to the notable presentations at the esteemed ESMO and ASCO conventions, providing a panoramic view of the contemporary advancements in ICI technology. Furthermore, the review underscores the imperative of continuous exploration in overcoming the extant challenges, such as the quest for reliable predictive biomarkers and the optimization of combinatorial strategies to surmount resistance and augment therapeutic efficacy. Through a holistic lens, this article elucidates the monumental impact of ICIs, marking a significant epoch in the odyssey towards rendering cancer a conquerable adversary.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"757-773"},"PeriodicalIF":2.4,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41154391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spine Instability Neoplastic Score (SINS) as a Predictive Tool in Conventional Radiotherapy: A Narrative Review. 脊柱不稳定新整形评分（SINS）作为常规放射治疗的预测工具：叙述性综述。

IF 2.4 4区医学

Cancer Investigation Pub Date : 2023-10-01 Epub Date: 2023-11-17 DOI: 10.1080/07357907.2023.2269566

Donato Pezzulla, Alessia Re, Savino Cilla, Milena Ferro, Carmela Romano, Paolo Bonome, Rossella Di Franco, Paolo Muto, Giancarlo Mattiucci, Francesco Deodato, Gabriella Macchia

引用次数: 0

Anxiety, Depression, and Coping Strategies during Chemotherapy Treatment: A Comparison of Older and Younger Adults with Advanced Cancer in Brazil. 化疗期间的焦虑、抑郁和应对策略：巴西老年人和年轻人晚期癌症的比较。

IF 2.4 4区医学

Cancer Investigation Pub Date : 2023-10-01 Epub Date: 2023-11-17 DOI: 10.1080/07357907.2023.2274033

Cristiane Decat Bergerot, Errol J Philip, Paulo Gustavo Bergerot, Marianne Razavi, David Lee, Karen Lynn Clark, Matthew Loscalzo, Sumanta Kumar Pal, William Dale

引用次数: 0

Perception, Cognition and Thought: Part IV Consciousness, Awareness, and "I". 知觉、认知和思想:第四部分意识、觉知和“我”。

IF 2.4 4区医学

Cancer Investigation Pub Date : 2023-10-01 Epub Date: 2023-08-23 DOI: 10.1080/07357907.2023.2248785

Gary H Lyman, Christopher H Lyman, Nicole M Kuderer

引用次数: 1

In Vitro and In Vivo Synergistic Antitumor Activity of Albumin-Coated Oleic Acid-Loaded Liposomes toward Hepatocellular Carcinoma. 白蛋白包被油酸脂质体对肝癌的体内外协同抗肿瘤活性研究。

IF 2.4 4区医学

Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2241083

Esmail M El-Fakharany, Mahmoud Ashry, Marwa M Abu-Serie, Khaled G Abdel-Wahhab, Doaa Galal El-Sahra, Hamada El-Gendi

{"title":"In Vitro and In Vivo Synergistic Antitumor Activity of Albumin-Coated Oleic Acid-Loaded Liposomes toward Hepatocellular Carcinoma.","authors":"Esmail M El-Fakharany, Mahmoud Ashry, Marwa M Abu-Serie, Khaled G Abdel-Wahhab, Doaa Galal El-Sahra, Hamada El-Gendi","doi":"10.1080/07357907.2023.2241083","DOIUrl":"https://doi.org/10.1080/07357907.2023.2241083","url":null,"abstract":"Hepatocellular carcinoma (HCC) is one of the most lethal and prevalent cancers, closely associated with cirrhosis and fibrosis. This study aimed to assess the antitumor activity of oleic acid-liposomes (uncoated liposomes) upon coating with albumin against HCC. The in vitro studies revealed the high safety of the prepared uncoated and albumin-coated liposomes to normal HFB-4 cells (EC100 of 35.57 ± 0.17 and 79.133 ± 2.92 µM, respectively) with significant anticancer activity against HepG-2 cells with IC50 of 56.29 ± 0.91 and 26.74 ± 0.64 µM, respectively. The albumin-coated liposomes revealed superior apoptosis induction potential (80.7%) with significant upregulation of p53 gene expression (<math><mo>></mo></math>7.0-fold), compared to OA. The in vivo study revealed that the administration of uncoated or albumin-coated liposomes (100 mg/kg) for six weeks markedly retarded the DENA-induced HCC in Wistar albino rates through regulating the liver enzymes, total bilirubin level, pro-inflammatory cytokines, and oxidative stress. Accordingly, the current study supports the in vitro and in vivo chemo-preventive feature of albumin-coated liposomes against HCC through modulation of apoptosis, improvement of the immune response, reduction of inflammation, and restoration of impaired oxidative stress, which is the first reported to the best of our knowledge.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"41 7","pages":"621-639"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10223087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma. 肿瘤分化作为临床分期T1bN0食管腺癌的预后标志物。

IF 2.4 4区医学

Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-09-04 DOI: 10.1080/07357907.2023.2255907

Ofer Margalit, Einat Shacham-Shmueli, Gal Strauss, Yu-Xiao Yang, Yaacov R Lawerence, Alon Ben Nun, Idan Levy, Kim A Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce Giantonio, Ronac Mamtani, Ben Boursi

引用次数: 0

Telomere Shortening of Barrett's Esophagus and Esophageal Adenocarcinoma in Japanese Patients. 日本巴雷特食管和食管腺癌患者端粒缩短。

IF 2.4 4区医学

Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2245897

Tomomitsu Tahara, Takuya Shijimaya, Jumpei Yamazaki, Takashi Tomiyama, Toshiro Fukui, Makoto Naganuma

引用次数: 0